GLUE Monte Rosa Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$16.37

Period return

-1.48 (-8.29%)

Volume

949.0K

2026-06-05O $17.45 H $17.8 L $16.25 C $16.37MA5 $17.75MA20 $18.63MA60 $18.03MA120 $18.69

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 12.LowBUY26 days ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 03. 18.LowBUY3 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 03. 18.LowBUY3 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $32.33 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
HQ: Boston, MA, United States
Fiscal year end

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	19,300	$317.49M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	14,000	$219.52M	0.00%	—	New position

Monte Rosa Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 12.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 03. 18.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 03. 18.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 01. 14.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 01. 08.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 01. 08.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy